Aratana Therapeutics, Inc. (PETX) was a big mover last session with its shares rising over 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend of the company, as the stock is now up nearly 30% in the past one-month time frame.
This biopharmaceutical company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate has also remained unchanged over the same period. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Aratana currently has a Zacks Rank #2 (Buy) while its Earnings ESP is positive.
Other well-placed Med-Drug stocks include Lannett Company, Inc. (LCI), Endocyte, Inc. (ECYT) and BioCryst Pharmaceuticals, Inc. (BCRX). While LCI and ECYT sport a Zacks Rank #1 (Strong Buy), BCRX carries the same Zacks Rank as Aratana.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment